JP2018501197A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501197A5 JP2018501197A5 JP2017525105A JP2017525105A JP2018501197A5 JP 2018501197 A5 JP2018501197 A5 JP 2018501197A5 JP 2017525105 A JP2017525105 A JP 2017525105A JP 2017525105 A JP2017525105 A JP 2017525105A JP 2018501197 A5 JP2018501197 A5 JP 2018501197A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 86
- 239000000427 antigen Substances 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 82
- 108091007433 antigens Proteins 0.000 claims description 82
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 30
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229950009791 durvalumab Drugs 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 229950007217 tremelimumab Drugs 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 4
- 102000045309 human NT5E Human genes 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 description 34
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077486P | 2014-11-10 | 2014-11-10 | |
| US62/077,486 | 2014-11-10 | ||
| US201562147329P | 2015-04-14 | 2015-04-14 | |
| US62/147,329 | 2015-04-14 | ||
| US201562188999P | 2015-07-06 | 2015-07-06 | |
| US62/188,999 | 2015-07-06 | ||
| PCT/EP2015/076111 WO2016075099A1 (en) | 2014-11-10 | 2015-11-09 | Binding molecules specific for cd73 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020142374A Division JP7069261B2 (ja) | 2014-11-10 | 2020-08-26 | Ｃｄ７３特異的結合分子及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501197A JP2018501197A (ja) | 2018-01-18 |
| JP2018501197A5 true JP2018501197A5 (enExample) | 2018-12-20 |
| JP6755866B2 JP6755866B2 (ja) | 2020-09-16 |
Family
ID=54478033
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525105A Active JP6755866B2 (ja) | 2014-11-10 | 2015-11-09 | Ｃｄ７３特異的結合分子及びその使用 |
| JP2020142374A Active JP7069261B2 (ja) | 2014-11-10 | 2020-08-26 | Ｃｄ７３特異的結合分子及びその使用 |
| JP2022076020A Pending JP2022115962A (ja) | 2014-11-10 | 2022-05-02 | Ｃｄ７３特異的結合分子及びその使用 |
| JP2024084037A Active JP7802110B2 (ja) | 2014-11-10 | 2024-05-23 | Ｃｄ７３特異的結合分子及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020142374A Active JP7069261B2 (ja) | 2014-11-10 | 2020-08-26 | Ｃｄ７３特異的結合分子及びその使用 |
| JP2022076020A Pending JP2022115962A (ja) | 2014-11-10 | 2022-05-02 | Ｃｄ７３特異的結合分子及びその使用 |
| JP2024084037A Active JP7802110B2 (ja) | 2014-11-10 | 2024-05-23 | Ｃｄ７３特異的結合分子及びその使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9938356B2 (enExample) |
| EP (2) | EP3218406B2 (enExample) |
| JP (4) | JP6755866B2 (enExample) |
| KR (3) | KR102698502B1 (enExample) |
| CN (2) | CN112778418B (enExample) |
| AU (1) | AU2015345202B2 (enExample) |
| CA (1) | CA2967118A1 (enExample) |
| CL (2) | CL2017001154A1 (enExample) |
| CY (1) | CY1124791T1 (enExample) |
| DK (1) | DK3218406T4 (enExample) |
| ES (1) | ES2877080T5 (enExample) |
| FI (1) | FI3218406T4 (enExample) |
| GB (1) | GB2537445A (enExample) |
| HR (1) | HRP20210888T4 (enExample) |
| HU (1) | HUE054339T2 (enExample) |
| IL (1) | IL251891B (enExample) |
| LT (1) | LT3218406T (enExample) |
| MX (1) | MX385320B (enExample) |
| MY (1) | MY191423A (enExample) |
| PL (1) | PL3218406T5 (enExample) |
| PT (1) | PT3218406T (enExample) |
| RS (1) | RS62003B2 (enExample) |
| RU (1) | RU2730665C2 (enExample) |
| SG (1) | SG11201703332SA (enExample) |
| SI (1) | SI3218406T2 (enExample) |
| SM (1) | SMT202100353T1 (enExample) |
| TW (1) | TWI710576B (enExample) |
| WO (1) | WO2016075099A1 (enExample) |
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| ES2749098T3 (es) * | 2014-05-13 | 2020-03-19 | Medimmune Ltd | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico |
| MX385320B (es) * | 2014-11-10 | 2025-03-18 | Medimmune Ltd | Moléculas de unión específicas para grupo de diferenciación 73 (cd73) y usos de las mismas. |
| WO2016075176A1 (en) * | 2014-11-11 | 2016-05-19 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| LT3221346T (lt) | 2014-11-21 | 2020-11-10 | Bristol-Myers Squibb Company | Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis |
| HUE050596T2 (hu) | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antitestek CD73 ellen és azok felhasználásai |
| ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
| WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| IL295230A (en) | 2016-03-04 | 2022-10-01 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| WO2017207739A1 (en) | 2016-06-02 | 2017-12-07 | Medimmune Limited | Antibodies to alpha-synuclein and uses thereof |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| PL3383916T3 (pl) * | 2017-01-24 | 2023-06-12 | I-Mab Biopharma Us Limited | Przeciwciała anty-cd73 i ich zastosowania |
| KR102584011B1 (ko) | 2017-03-16 | 2023-09-27 | 이나뜨 파르마 에스.에이. | 암 치료를 위한 조성물 및 방법 |
| US20210107989A1 (en) * | 2017-04-04 | 2021-04-15 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
| BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
| EP3630046B1 (en) | 2017-05-30 | 2024-12-25 | The Board of Regents of the University of Oklahoma | Anti-doublecortin-like kinase 1 antibodies and methods of use |
| CN110785187B (zh) * | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018237173A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| BR112020001188A2 (pt) | 2017-07-26 | 2020-07-28 | Chong Kun Dang Pharmaceutical Corp. | composição para prevenir ou tratar câncer que compreende um agente de disrupção vascular e inibidor de ponto de verificação imunológico |
| BR112020006809A2 (pt) | 2017-10-06 | 2020-10-06 | Innate Pharma | anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| JP7084990B2 (ja) | 2017-10-13 | 2022-06-15 | ハープーン セラピューティクス，インク． | 三重特異性タンパク質と使用方法 |
| CA3083949A1 (en) | 2017-11-30 | 2020-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| US12084514B2 (en) | 2017-12-04 | 2024-09-10 | The Board Of Regents Of The University Of Oklahoma | Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof |
| US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| CN110240654A (zh) | 2018-03-07 | 2019-09-17 | 复旦大学 | 结合cd73的抗体-药物偶联物 |
| WO2019170131A1 (zh) | 2018-03-07 | 2019-09-12 | 复旦大学 | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 |
| SG11202007199XA (en) | 2018-03-09 | 2020-09-29 | Phanes Therapeutics Inc | Anti-cd73 antibodies and uses thereof |
| BR112020017382A2 (pt) * | 2018-03-09 | 2021-01-26 | Agenus Inc. | anticorpos anti-cd73 e métodos de uso dos mesmos |
| MX2020010604A (es) | 2018-04-12 | 2020-10-20 | Bristol Myers Squibb Co | Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1). |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| KR20250151605A (ko) | 2018-06-01 | 2025-10-21 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| PT3807316T (pt) | 2018-06-18 | 2024-07-29 | Innate Pharma | Composições e métodos para tratamento de cancro |
| CN113166153B (zh) | 2018-07-05 | 2024-11-01 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| BR112021007902A2 (pt) * | 2018-11-12 | 2021-11-16 | Jiangsu Hengrui Medicine Co | Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos |
| CN111499747B (zh) * | 2019-01-11 | 2022-03-18 | 康诺亚生物医药科技（成都）有限公司 | 一种抗cd73单克隆抗体及其应用 |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| JOP20210164A1 (ar) | 2019-01-11 | 2023-01-30 | Omeros Corp | طرق وتركيبات علاج السرطان |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN113795267A (zh) * | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| CN113874397A (zh) | 2019-03-29 | 2021-12-31 | 艾库斯生物科学有限公司 | 利用鉴定的腺苷指纹治疗癌症 |
| AU2020254100B9 (en) | 2019-04-02 | 2024-11-21 | Medimmune, Llc | Anti-CD73, anti-PD-L1 antibodies and chemotherapy for treating tumors |
| CN117946274B (zh) * | 2019-06-19 | 2026-02-17 | 杭州博之锐生物制药有限公司 | 抗cd73抗体及其应用 |
| CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN113454121B (zh) * | 2019-08-21 | 2022-03-08 | 和铂医药(上海)有限责任公司 | 抗cd73抗体及其应用 |
| BR112022003170A2 (pt) * | 2019-08-30 | 2022-05-17 | Genentech Inc | Desenvolvimento de uma plataforma de hibridoma eficiente para descoberta de anticorpo terapêutico |
| PE20220708A1 (es) | 2019-09-06 | 2022-05-04 | Symphogen As | Anticuerpos anti-cd73 |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| KR20220100929A (ko) * | 2019-11-15 | 2022-07-18 | 젠자임 코포레이션 | 이중파라토프성 cd73 항체 |
| TWI873265B (zh) | 2020-01-03 | 2025-02-21 | 美商英塞特公司 | 抗ｃｄ７３抗體及其用途 |
| PH12022551621A1 (en) | 2020-01-03 | 2023-10-23 | Incyte Corp | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| EP4132975A4 (en) * | 2020-04-09 | 2024-10-23 | Aprilbio Co., Ltd | MONOCLONAL ANTIBODIES AND THEIR ANTIGEN-BINDING FRAGMENTS FOR SUPPRESSING THE CD73 IMMUNE CHECKPOINT AND USES THEREOF |
| KR20230004725A (ko) * | 2020-04-22 | 2023-01-06 | 아케소 바이오파마, 인크. | 항-cd73 항체 및 이의 용도 |
| PH12022552785A1 (en) * | 2020-04-22 | 2024-03-25 | Akeso Biopharma Inc | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| CN115551889A (zh) * | 2020-05-12 | 2022-12-30 | 普米斯生物技术(珠海)有限公司 | 抗cd73抗体及其用途 |
| EP4159763A4 (en) * | 2020-05-29 | 2024-06-12 | BrightPath Biotherapeutics Co., Ltd. | ANTI-CD73 ANTIBODIES AND USE THEREOF |
| WO2021247188A1 (en) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
| CN111714642A (zh) * | 2020-06-18 | 2020-09-29 | 复旦大学 | Cd73抗体-药物偶联物的应用 |
| JP2023532234A (ja) * | 2020-06-22 | 2023-07-27 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ｃｄ７３抗体とその用途 |
| US20250262293A1 (en) | 2020-07-07 | 2025-08-21 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| CN114075289B (zh) * | 2020-08-17 | 2024-07-02 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| CN114380915B (zh) * | 2020-10-19 | 2024-03-22 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| AU2021363350A1 (en) * | 2020-10-23 | 2023-06-22 | Akeso Biopharma, Inc | Anti-cd73 antibody and use thereof |
| IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| CN114456268B (zh) * | 2020-11-09 | 2023-08-18 | 江苏中新医药有限公司 | 抗胞外-5’-核苷酸酶的抗体序列 |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Ｃｄ７３的抗原結合蛋白及其應用 |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| KR20230157940A (ko) | 2020-12-29 | 2023-11-17 | 인사이트 코포레이션 | A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법 |
| CN113061177B (zh) * | 2020-12-31 | 2022-07-01 | 浙江大学 | 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法 |
| CN113045659B (zh) * | 2021-03-18 | 2022-03-18 | 上海近岸科技有限公司 | 抗cd73人源化抗体 |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| US20240269276A1 (en) * | 2021-05-28 | 2024-08-15 | Harbour Biomed (Shanghai) Co., Ltd. | Specific binding protein targeting pd-l1 and cd73 |
| MX2024000674A (es) | 2021-07-13 | 2024-02-07 | BioNTech SE | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| AU2023212216A1 (en) | 2022-01-25 | 2024-08-08 | CSPC Megalith Biopharmaceutical Co., Ltd. | Anti-cd73 antibody and use thereof |
| US12187806B2 (en) | 2022-03-04 | 2025-01-07 | Development Center For Biotechnology | Anti-CD73 antibodies and use thereof |
| US20250195679A1 (en) * | 2022-03-14 | 2025-06-19 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Antibody-drug conjugate and use thereof |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US12487299B2 (en) | 2022-06-20 | 2025-12-02 | Shanghai United Imaging Healthcare Co., Ltd. | Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices |
| CN117304316A (zh) * | 2022-06-22 | 2023-12-29 | 复旦大学 | 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途 |
| CN115991772B (zh) * | 2022-08-12 | 2023-09-01 | 南京蓬勃生物科技有限公司 | 抗cd73抗体或其抗原片段及其应用 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2023403103A1 (en) | 2022-12-01 | 2025-07-10 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| CN121336009A (zh) * | 2023-05-07 | 2026-01-13 | 生物蛋白有限公司 | 用于治疗衰老细胞的蛋白治疗剂 |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025162964A1 (en) | 2024-01-30 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE3588239T3 (de) | 1985-03-30 | 2007-03-08 | Kauffman, Stuart A., Santa Fe | Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| FI915411A0 (fi) | 1989-05-16 | 1991-11-15 | Scripps Research Inst | Samexpression av heteromeriska receptorer. |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| NZ241119A (en) | 1990-12-20 | 1993-06-25 | Ixsys Inc | Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
| WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
| KR20020091170A (ko) * | 2000-03-31 | 2002-12-05 | 아이덱 파마슈티칼즈 코포레이션 | Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용 |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| US7158164B2 (en) | 2003-08-29 | 2007-01-02 | Fuji Photo Film Co., Ltd. | Thermal development method and apparatus |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| EP1685161A1 (en) | 2004-08-30 | 2006-08-02 | Lonza Biologics plc | Affinity- plus ion exchange-chromatography for purifying antibodies |
| EP2078732B1 (en) † | 2006-07-10 | 2015-09-16 | Fujita Health University | Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry |
| WO2008008284A2 (en) * | 2006-07-14 | 2008-01-17 | The Regents Of The University Of California | Cancer biomarkers and methods of use threof |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| WO2009092014A1 (en) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| JP5511686B2 (ja) * | 2008-12-26 | 2014-06-04 | 協和発酵キリン株式会社 | 抗ｃｄ４抗体 |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| PL2506871T3 (pl) | 2009-11-30 | 2017-03-31 | Janssen Biotech, Inc | Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi |
| MX341925B (es) | 2010-03-29 | 2016-09-07 | Zymeworks Inc | Anticuerpos con funcion efectora suprimida o mejorada. |
| MX339621B (es) * | 2010-04-13 | 2016-06-02 | Celldex Therapeutics Inc * | Anticuerpos que se unen a cd27 humano y uso de los mismos. |
| KR101818274B1 (ko) | 2010-05-27 | 2018-01-12 | 머크 샤프 앤드 돔 코포레이션 | 개선된 특성을 갖는 항체의 제조 방법 |
| EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| DK2771022T3 (da) | 2011-10-11 | 2020-09-28 | Viela Bio Inc | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf |
| WO2014153424A1 (en) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| KR102536786B1 (ko) † | 2014-10-10 | 2023-05-26 | 이나뜨 파르마 에스.에이. | Ｃｄ７３ 차단 |
| MX385320B (es) * | 2014-11-10 | 2025-03-18 | Medimmune Ltd | Moléculas de unión específicas para grupo de diferenciación 73 (cd73) y usos de las mismas. |
| HUE050596T2 (hu) † | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antitestek CD73 ellen és azok felhasználásai |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2015
- 2015-11-09 MX MX2017005976A patent/MX385320B/es unknown
- 2015-11-09 RS RS20210770A patent/RS62003B2/sr unknown
- 2015-11-09 ES ES15791298T patent/ES2877080T5/es active Active
- 2015-11-09 FI FIEP15791298.1T patent/FI3218406T4/fi active
- 2015-11-09 KR KR1020177013490A patent/KR102698502B1/ko active Active
- 2015-11-09 HU HUE15791298A patent/HUE054339T2/hu unknown
- 2015-11-09 LT LTEP15791298.1T patent/LT3218406T/lt unknown
- 2015-11-09 PT PT157912981T patent/PT3218406T/pt unknown
- 2015-11-09 JP JP2017525105A patent/JP6755866B2/ja active Active
- 2015-11-09 MY MYPI2017701628A patent/MY191423A/en unknown
- 2015-11-09 AU AU2015345202A patent/AU2015345202B2/en active Active
- 2015-11-09 EP EP15791298.1A patent/EP3218406B2/en active Active
- 2015-11-09 GB GB1519761.9A patent/GB2537445A/en not_active Withdrawn
- 2015-11-09 KR KR1020247027896A patent/KR102781223B1/ko active Active
- 2015-11-09 KR KR1020257007790A patent/KR20250037600A/ko active Pending
- 2015-11-09 EP EP21157088.2A patent/EP3901176A1/en active Pending
- 2015-11-09 US US14/936,233 patent/US9938356B2/en active Active
- 2015-11-09 HR HRP20210888TT patent/HRP20210888T4/hr unknown
- 2015-11-09 WO PCT/EP2015/076111 patent/WO2016075099A1/en not_active Ceased
- 2015-11-09 DK DK15791298.1T patent/DK3218406T4/da active
- 2015-11-09 CN CN202011361822.4A patent/CN112778418B/zh active Active
- 2015-11-09 SG SG11201703332SA patent/SG11201703332SA/en unknown
- 2015-11-09 CN CN201580060993.4A patent/CN107001472B/zh active Active
- 2015-11-09 SI SI201531619T patent/SI3218406T2/sl unknown
- 2015-11-09 PL PL15791298.1T patent/PL3218406T5/pl unknown
- 2015-11-09 CA CA2967118A patent/CA2967118A1/en active Pending
- 2015-11-09 SM SM20210353T patent/SMT202100353T1/it unknown
- 2015-11-09 RU RU2017117596A patent/RU2730665C2/ru active
- 2015-11-10 TW TW104137067A patent/TWI710576B/zh active
-
2017
- 2017-04-24 IL IL251891A patent/IL251891B/en active IP Right Grant
- 2017-05-08 CL CL2017001154A patent/CL2017001154A1/es unknown
-
2018
- 2018-02-23 US US15/903,649 patent/US10287362B2/en active Active
-
2019
- 2019-04-04 US US16/375,051 patent/US10556968B2/en active Active
- 2019-11-08 US US16/678,165 patent/US11525012B2/en active Active
-
2020
- 2020-08-26 JP JP2020142374A patent/JP7069261B2/ja active Active
- 2020-12-29 CL CL2020003409A patent/CL2020003409A1/es unknown
-
2021
- 2021-06-23 CY CY20211100552T patent/CY1124791T1/el unknown
-
2022
- 2022-05-02 JP JP2022076020A patent/JP2022115962A/ja active Pending
- 2022-11-30 US US18/060,204 patent/US20230340152A1/en active Pending
-
2024
- 2024-05-23 JP JP2024084037A patent/JP7802110B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501197A5 (enExample) | ||
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| JP2023134490A (ja) | リンパ球における阻害経路の中和 | |
| JP7274426B2 (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| JP2017535257A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| JP2019514844A5 (enExample) | ||
| TW201718650A (zh) | Ｐｄ－ｌ１抗體 | |
| JP2019513008A (ja) | Ｂｔｌａに対して特異性を有する抗体及びその使用 | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| JP2020512388A5 (enExample) | ||
| JP2021523170A (ja) | 癌の処置 | |
| JP2026049003A (ja) | Ｔｉｇｉｔとｃｄ１１２ｒ遮断 | |
| JP2025507938A (ja) | 抗ｐｄ－ｌ２抗体 | |
| TWI887285B (zh) | 抗ｇａｒｐ抗體與免疫調節劑之組合及其用途 | |
| CA3233512A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| HK40110316A (en) | Neutralization of inhibitory pathways in lymphocytes | |
| EP4313311A1 (en) | Multispecific binding moieties comprising novel pd-1 binding domains | |
| CN113368232A (zh) | 多特异性抗原结合蛋白及其应用 | |
| NZ788279B2 (en) | Anti-tim-3 antibodies and methods of use thereof | |
| RU2021106602A (ru) | 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака |